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BACKGROUND: Local recurrence is the major cause of treatment failure in head and neck 
cancer patients and 50-60% of patients die as a direct consequence of recurrent disease. These 
recurrent tumours is also associated with significant problems related to symptom control and 
markedly reduces quality of life. 
 
AIMS AND OBJECTIVES: To assess the immediate locoregional response rates and acute 
toxicities of the treatment of unresectable locoregionally recurrent squamous cell carcinomas of 
the head and neck treated with reirradiation and oral capecitabine. 
 
MATERIALS & METHODS: The study was conducted in MMC, BIRO, RGGGH including 
30 Eligible patients were selected for re-irradiation in case of inoperable and/or unresectable 
tumours treated with conventional fractionation 2Gy per fraction for 5 days a week, up to a total 
cumulative dose of 120Gy including the previous RT dose with T.Capecitabine 500mg BD on 
treatment days. 
 
RESULTS: The median time between the first course of radiotherapy and second was 20 
months. The overall response rate in our study was 90% including 16 patients with a complete 
response, 11 patients with a partial response and 3 patients with stable disease. Grade 2 and 3 
pharyngeal toxicities noted in 13 and 11 cases respectively. Grade 3 mucositis occurred in 6 
patients. The cumulative median lifetime dose was 116 Gy. 
 
 
CONCLUSION:  
This is the first prospective single institutional trial testing reirradiation plus chemotherapy for 
recurrent SCCHN in our BIRO, RGGGH. We conclude that reirradiation with chemotherapy up 
to a total dose of 60GY is feasible and effective in carefully selected patients with acceptable 
acute toxicities. 
 
KEY WORDS: REIRRADIATION, CAPECITABINE, RECURRENCE, UNRESECTABLE 
HEAD AND NECK CANCERS, MUCOSITIS, DYSPHAGIA. 
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                                          Cancer is a complex genetic disease derived from the 
accumulation of various genetic changes. These genetic alterations include 
activation of proto oncogenes and inactivation of tumor suppressor genes. A 
number of specific genetic events have been identified in the progression of head 
and neck squamous cell carcinoma (HNSCC). It has been estimated that up to 10% 
of all cancers have a strong hereditary component. A clustering of oral cancer has 
been seen in certain ethnic groups, and an increased risk of cancer has been noted 
among relatives of patients with one head and neck cancer. Several studies have 
suggested a threefold higher risk of developing an oropharyngeal cancer in 
populations that have a first-degree relative with HNSCC.  
 
                                                 In a developing country like India there is 
phenomenal improvement in medical and research field over the past years. The 
noninfectious diseases becomes the majority cause for morbidity and mortality. 
The infectious diseases on a downfall path comparing to the noninfectious 
diseases. In India cancer is increasingly occurring among the adults. Especially 
head and neck cancers among the younger and older adults.  
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                               These cancers occur according to the geographical area and 
environmental factors. There is a gross variation of occurrence in population. The 
incidence remains high in the developed countries. Comparing to developed 
countries the incidence of head and neck cancer remains in the higher side. In India 
the most common head and neck malignancies are those of oral cavity and 
pharynx.  Oral cavity and pharynx cancers stand as third most common cancer in 
males and as the fourth common cancer in females in developing countries 
 
                                 The primary reason for increased occurrence of head and neck 
cancer was tobacco chewing and smoking. The increasing number of cancers 
results in mortality. Increased risk of buccal mucosa and oropharyngeal cancers 
occurs in persons using tobacco products. Betel nut chewing and tobacco produces 
morbidity which influence the quality of life. The effect of alcohol and tobacco 
also influence the development of head and neck cancers. Pipe and cigar smokers 
have high incidence of lip and oral cavity cancers because of concentrated 
carcinogens in these regions. 
                                         In summary, the poor socio economic status, oral 
consumption of tobacco in various forms, use of lime with betel nuts and betel leaf, 
smoking and alcohol intake together contribute to two lakh cases of head and neck 
cancer per year in India. 
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GENETICS: 
                                 An emerging area of study centers on the prevalence of 
specific polymorphisms in enzymes that are involved in the detoxification of 
several tobacco smoke–derived carcinogens. One larger study of 162 
patients with head and neck cancer and 315 healthy controls suggested that 
certain glutathione S-transferase (GST) genotypes represented independent 
risk factors for head and neck cancer. Some studies also have shown a two- 
to three fold risk for the GSTM1 and GSTT1 null genotypes, whereas others 
have shown no increase in HNSCC risk. Others also have found that the 
repair capacity of peripheral lymphocytes or their ability to repair 
carcinogen-induced chromatic breaks may also define a certain risk for head 
and neck cancer. Cytogenetic approaches have given us some insights into 
potential areas of deletion and amplification involved in the progression of 
head and neck cancer. Short-term cultures of primary tumors have proven 
more reliable for the assessment of complex, chromosome abnormalities and 
rearrangements. These studies have already demonstrated consistent 
chromosomal abnormalities and the presence of important alterations. .  
Studies have shown that p63 is amplified and that Np63 isotypes are 
overexpressed in HNSCC and enhance oncogenic growth in vitro and in 
vivo. P53 appears to regulate its family member by physically binding with 
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Np63 and mediating its degradation. A report has demonstrated that Np63 
associates with the B56 regulatory subunit of protein phosphatase 2A and 
glycogen synthase kinase-3 (GSK3), leading to a dramatic inhibition of 
protein phosphatase 2A–mediated GSK3 reactivation. The inhibitory effect 
of  Np63 on GSK3  mediated a decrease in phosphorylation levels of  -
catenin, which induces intra nuclear accumulation of  -catenin and activates  
-catenin–dependent transcription. These results suggest that Np63 isotypes 
act as positive regulators of the  -catenin signaling pathway, providing a 
basis for their oncogenic properties in SCC. 
 
 
RATIONALE FOR PRESENTATION IN ADVANCED STAGES: 
                                                 In India around 50-60% of head and neck cancers 
present in locally advanced stage. In our institute 60- 75 % patients present with 
advanced stage. The reason behind this involves various factors influencing the 
occurrence of head and neck cancers. Some predicted factors are poor 
socioeconomic status, lack of awareness. Some social factors include education, 
transport facilities and nosocomephobia.  
Kumar. S et al. stated some psychosocial beliefs like  
 6 
1. Cancer a curse. 
2. Ill-fated to have cancer. 
3. Trivial ulcers in the mouth are self-limiting. 
4. The fear that the prolonged treatment will render the family stressful.  
                    Main important thing was patient attenders advising the patients 
to seek local treatment and unrecognised treatment practices. Most of the patients 
land up with advanced stages with increased tumour growth. They seek medical 
attention after increased tumour burden to the higher centres. 
HISTOPATHOLOGY 
 
Squamous cell carcinomas constitute most common variety of histology. Its 
variants like  
1. Lymphoepithelioma.  
2. Spindle cell carcinoma.  
3. Verrucous carcinoma. 
4. Undifferentiated carcinoma.  
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The less common histology includes  
5. Lymphoma. 
6. Small cell neuro endocrine carcinoma. 
7. Extramedullary Plasmacytoma. 
8. Mucoepidermoid carcinoma. 
9. Adenoid cystic carcinoma. 
10. Melanomas. 
 Squamous cell carcinomas constitute 97% of cancers in our institute. 
 
TREATMENT OVERVIEW: 
 
The treatment of locally advanced head and neck carcinomas include 
1. Surgery. 
2. Radiotherapy. 
3. Chemotherapy.  
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These modalities depends on site of tumour, histology and patient 
preferences. The functional outcome, resect ability, general condition of the patient 
has a additive factor.  Hence despite recent advances the management remains a 
great challenge. 
 
SURGERY VS RADIATION: 
 
These are the main treatment modalities used in H&N carcinomas. The 
chemotherapy added to enhance the effect of radiation treatment. 
The advantages of surgery compared to radiotherapy are  
1. Only limited amount of tissue is exposed to treatment. 
2. Shorter treatment time. 
3. Acute and late radiation sequel can be avoided. 
4. Radiation can be reserved for future recurrences or second primaries. 
 The most important advantage of radiation therapy compared to surgery 
1. Organ preservation  
2. Function preservation.  
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         Comparing to elective treatment of neck nodes, elective irradiation of 
neck can be done with little added morbidity. If radiation fails there is 
always option of salvage surgery. In surgical failure recurrence occurs at the 
scar site. It is difficult to distinguish from normal surgical scarring. Hence 
the diagnosis is often delayed. Re-excision is also difficult under these 
circumstances. 
CONCURRENT CHEMO RADIATION 
                                   Concurrent chemoradiation is associated with improved loco 
regional control and overall survival. The use of chemotheraphy will potentiate the 
effect of radiation. A recent update of Meta- analysis of chemotherapy on head and 
neck cancer (MACH-NC) showed [CCRT vs RT] 
1. Adding chemotherapy along with radiation results in 19 % reduction in 
risk of death.  
2. 8% improvement in overall survival. 
Majority of these benefits are derived from concurrent chemo radiation. The 2 % 
improvement in survival by induction chemotherapy is not statistically significant. 
Even though concurrent chemo radiation increases the toxicities of radiation, it 
exerts a good loco regional and systemic control. 
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RECURRENCE SETTING: 
                               Local recurrence is the major cause of treatment failure in head 
and neck cancer patients and 50-60% of patients die as a direct consequence of 
recurrent disease. These recurrent tumours is also associated with significant 
problems related to symptom control and markedly reduces quality of life.  
                              As most recurrences occur in the first 2yr after primary 
treatment and 80% arise in previously high dose irradiated volumes, it is obvious 
that the management of these recurrences is a challenging clinical problem. If 
resectable, surgery is the treatment of choice for these lesions and salvage rates 
tend to vary based on the site of primary. Due to tumour location and extent, 
surgery is often irradical with close or positive margins. The risk of morbidity is 
also higher as a result of radiation induced tissue changes which complicate tissue 
healing. 
                            Only 15-20% of patients will be able to undergo salvage surgery 
because of the extent of the disease, medical contraindications or patient refusal 
and also radiation induced changes which complicate healing. Palliative 
chemotherapy comprises only the management for previously irradiated, 
unresectable recurrent head and neck cancer. This approach has offered limited 
palliation with medial survival ranging between 5 and 9 months. Patients receiving 
supportive care alone have a poor median survival, between 3 and 5 months. 
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Therefore Salvage therapy options for patients with unresectable, previously 
irradiated squamous cell carcinoma of the head and neck (SCCHN) are limited It is 
important to know that a reduction in tumour size in those cases may still improve 
quality of life. The median survival time using chemotherapy alone does not 
exceed 6 months. This suggests the need for new therapeutic approaches.  
 
 
                                  The agent which increases the efficacy of the reirradiation 
without considerable toxicity must be selected. Capecitabine is orally available, 
which has shown remarkable efficacy in combination with radiotherapy. The 
conversion of capecitabine to its active metabolite depends on the enzyme 
thymidine phosphorylase, which is expressed in tumours at a higher level than in 
normal tissue. In addition, irradiation increases the expression of thymidine 
phosphorylase in tumors, further enhancing the local activity of capecitabine 
within the irradiated tumor volume. These properties of capecitabine make it an 
ideal combination partner for achieving a topographically restricted sensitizing 
effect within the irradiated area. 
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CHEMOTHERAPY FOR RECURRENT OR METASTATIC DISEASE: 
 
Patients with recurrent or metastatic head and neck SCCs have a median survival 
of 6 to 9 months, and a 1-year survival rate of 20% to 40% when treated with 
chemotherapy alone.
 
The survival benefit associated with the use of chemotherapy 
compared to best supportive care only in these patients has not been well studied. 
Although selected patients may derive apparent significant prolongations in 
survival, average survival improvements appear small at best. Morton et al. 
reported a 2-month improvement in median survival after treatment with cisplatin, 
with or without bleomycin, compared with no treatment. The duration of responses 
is typically measured in weeks to months, not years; survival beyond 2 years is 
infrequent; cures are anecdotal. Thus, the primary intent of chemotherapy in this 
setting is to achieve tumor regression with the hope that the potential palliative 
benefit and possible modest survival improvement will outweigh the side effects of 
treatment. Unfortunately, most clinical trials have historically used response rate 
and toxicity reporting as surrogate measures for outcomes of greater priority to the 
patients, such as palliation of specific symptoms (e.g., pain), improvement in 
function (e.g., swallowing), or overall quality of life. 
A number of drugs have been demonstrated in clinical trials to have activity in 
head and neck SCCs, and the list is well summarized in prior reviews. The most 
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commonly used include methotrexate, cisplatin, carboplatin, 5-fluorouracil, 
paclitaxel, and docetaxel, with reported major response rates ranging from 15% to 
42%. Among other drugs with reported major response rates of 15% or greater are 
bleomycin, cyclophosphamide, doxorubicin, hydroxyurea, ifosfamide, irinotecan, 
oral uracil, and ftorafur (with leucovorin), pemetrexed, vinblastine, and 
vinorelbine. Some of these agents (e.g., cyclophosphamide, doxorubicin, 
hydroxyurea) have their activity based on reported assessment in a limited number 
of patients from over 2 decades ago, an era when methods and criteria for response 
assessment may have differed from current standards. Anticipated response rates 
and toxicity profiles may vary based on patient selection and drug schedule. Poor 
performance status is associated with both lower response rates and greater 
potential for toxicity. The larger the amount of prior treatment also adversely 
affects response rates. 
                                Methotrexate is a historic standard drug used in the recurrent 
or metastatic disease setting. The typical standard dosing is 40 mg/m
2
 
intravenously weekly, with dose attenuation or increase (up to 60 mg/m
2
) based on 
toxicity, with mucositis being a frequent reason for dose adjustment. The favorable 
side effect profile and convenience of administration of methotrexate make it well 
suited for use in this patient population in which medical comorbidity is common, 
as is more advanced age. Higher doses have been compared to standard dosing in 
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randomized trials: response rates increase as dose toxicity, without a significant 
improvement in overall survival. Similarly, newer analogues of methotrexate (e.g., 
edatrexate) have not been shown in phase 3 trials to offer a therapeutic advantage. 
                                Cisplatin is a cornerstone drug in the modern management of 
head and neck cancer. Cisplatin is customarily dosed at 75 to 100 mg/m
2
 
intravenously every 3 to 4 weeks. The potential for renal (i.e., increase in 
creatinine, electrolyte abnormalities), otologic (i.e., high-frequency hearing loss, 
tinnitus), neurologic (i.e., peripheral neuropathy), and gastrointestinal (i.e., nausea 
and vomiting) toxicity are widely appreciated, but these risks are manageable if 
patients are appropriately screened for therapy, monitored closely during it, and 
state of the art antiemetics are applied. Further dose escalation of cisplatin has not 
been established to improve outcome. A randomized trial comparing 60 mg/m
2
 
versus 120 mg/m
2
 of cisplatin failed to demonstrate a significant improvement in 
response or survival. Carboplatin is the best studied and most commonly used 
platinum analogue in head and neck cancer. It has less renal, otologic, neurologic, 
and gastrointestinal toxicity than the parent drug, and is also easier to administer. 
The tradeoff is that it is more bone marrow-suppressive and may be somewhat less 
active. This last issue is more of a concern in the definitive treatment setting in 
which cure is a central end point, as opposed to the palliative setting, when patients 
often seek a less toxic alternative treatment. Although taxanes as a class have 
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significant activity in head and neck SCCs, hopes of clinically significant 
improvement in survival in the palliative setting with the introduction of these 
agents have yet to be realized. Neither paclitaxel or docetaxel has been 
demonstrated in random assignment trials to be clearly superior to methotrexate 
with regard to survival as an end point. Initial studies with paclitaxel used a dose of 
250 mg/m
2
 intravenously over 24 hours with growth factor support. In an Eastern 
Cooperative Oncology Group (ECOG) trial, 12 of 30 patients (40%) had a partial 
(8 patients) or complete (4 patients) response. However, grade 3 or greater 
neutropenia occurred in 91% of patients, and there were two deaths. Less 
cumbersome to administer and less toxic schedules are commonly used in practice 
(e.g., 135–225 mg/m2 intravenously over 3 hours every 3 weeks; 80–100 mg/m2 
weekly), although their relative efficacies have not been well evaluated. A 
paclitaxel schedule that provides more prolonged exposure to the drug may be 
more efficacious, although a phase 2 trial of 120 to 140 mg/m
2
 every 96 hours 
yielded disappointing results even in treatment-naïve patients (major response rate, 
13%). Other toxicities, besides myelosuppression, include sensory neuropathy, 
alopecia, allergic reactions, and arrhythmia, although cardiac monitoring is not 
required. 
                                  Docetaxel appears less neuropathic than paclitaxel, but fluid 
retention and hematologic toxicity may be more problematic. A typical dose is 60 
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to 100 mg/m
2
 intravenously over 1 hour. Initial studies evaluated the efficacy of 
the 100 mg/m
2
 dose level, with major response rates ranging from 21% to 42% an 
excellent performance status is required for this higher dose. Lower doses may 
offer similar efficacy and better tolerance. A multicenter study evaluating a 60 
mg/m
2
 dose level reported a major response rate of 22%.
 
  As with paclitaxel, 
weekly schedules are applied in practice, but the relative efficacy of a weekly 
versus every-3-weeks schedule is not well studied. Although initial studies 
evaluated a bolus schedule for 5-fluorouracil, an infusional program of 1,000 
mg/m
2
/day over 96 to 120 hours appears more efficacious in head and neck cancer. 
Infusional 5-fluorouracil is associated with more mucositis and diarrhea than a 
bolus schedule, so the shorter infusion (i.e., 96 hours) is typically applied in 
patients who are pretreated and have received prior head and neck RT. 
EGFR is highly expressed in most head and neck SCCs, and the degree of 
expression is inversely associated with prognosis. As such, there has been keen 
interest in drugs that target the receptor itself or steps downstream. Cetuximab, a 
chimeric immunoglobulin G antibody that binds the receptor, has been approved 
by the U.S. Food and Drug Administration for use in patients with disease 
refractory to platin-based therapy. As summarized in Table 72.7, the response rates 
in this refractory setting are similar, 10% to 13%, whether cetuximab is used alone 
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or combined with platin-based therapy. Disease stabilizations were more common, 
but median survivals remained disappointing, ranging from 5.2 to 6.1 months. 
The small molecule tyrosine kinase inhibitors gefitinib and erlotinib offer no 
efficacy advantage in similar refractory patients. Major response rates and median 
survivals ranged from 0% to 15% and 5.9 to 8.1 months, respectively. A large 
randomized trial (486 patients) compared gefitinib (250 or 500 mg daily) to 
methotrexate and demonstrated no survival improvement with either gefitinib dose. 
There were more tumor hemorrhage-type events on the gefitinib arms (8.9% and 
11.4% vs. 1.9%). 
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CONVENTIONAL FRACTIONATION: 
                           Radiotherapy alone has been the standard nonsurgical 
therapy for locally advanced disease. The conventional fractionation uses 200 cGy 
per fraction as a standard universal dose for head and neck cancers. Five fractions 
per week is used and two days of no fractions for patient and physician 
convenience.  Total dose of 60 to 70 Gy is used in 2D technique for all patients 
with head and neck cancers. This was started by Fletcher without any strong 
radiobiological basis. It provides acceptable compromise between tumour control 
and normal tissue complications. In order to improve the therapeutic ratio, the 
tumour control probability should be increased and normal tissue complication 
probability should be decreased. In order to achieve this target people started trying 
modified fractionation. 
 
CHEMO RADIATION: 
                    Most trials used sequential or induction chemotherapy followed by 
radiotherapy. The Department of Veterans Affairs Laryngeal Cancer study Group 
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conducted a study. The study comprises locally advanced laryngeal cancer with the 
purpose of showing feasibility of chemotherapy. The study comprises two arms. 
1. Induction chemotherapy followed by radiotherapy with surgery reserved for 
residual or recurrent lesions 
                                                          VS 
2. Surgery followed by post- operative radiotherapy.  
                             Control arm received three cycles of induction chemotherapy 
[CDDP+5FU]. The patients were assessed after two cycles of chemotherapy. Any 
patient who failed to attain partial response immediate surgery  radiotherapy. 
Other patients were allowed to complete three cycles of chemotherapy  
radiotherapy. 
                           RESULTS: Overall survival was same in both arms. The 3 year 
survival rate was 52%. The loco regional recurrences were greater in the control 
arm (13% vs 3% p=0.001). Salvage surgery in recurrent cases produce no 
difference in overall survival. Distant relapses were decreased in the chemo arm 
(12 % vs 18 % p=0.001). Overall survival could not be improved in chemotherapy 
arm. 75% in the chemotherapy arm retained functional larynx.  
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CONCURRENT CHEMORADIATION  
CCRT:  In the evolution of curative radiation treatment CCRT plays an important 
role. Achieving a favorable balance between tumor cell kill and normal tissue  
 
Toxicity is achievable with cure rates. The function and reserve capacity of tissues 
and organs are impaired result of previous treatment. The increase in the tumor cell 
kill of reirradiation should be achieved improve the therapeutic index. Therapeutic 
index involves not only increased tumour cell kill but also decreased toxicities. 
There are two regions where reirradiation often is combined with concomitant 
Chemotherapy. 1. Head and neck tumors. 2.  Rectal cancer.  
                        Systematic experimental models is used for development of first-
line Combinations. Their evaluation through a classic series of clinical trials is 
warranted. This involves randomized phase III studies. Development of sound 
combination regimens for reirradiation is just at its beginning. The clinical 
situation is complicated by more heterogeneous tumors with resistant tissues. With 
changes in physiological and micro environmental changes over time is in need of 
new modalities required for treatment approaches.  
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The combination of radiation therapy and chemotherapy has been shown to be 
superior. Responses involving the radiation alone in both tumor response and 
patient survival is having decreased response. New classes of agents are 
Being developed and rapidly introduced to clinical use.  
 
These agents target one or more of the processes that play important roles in the 
malignant phenotype. These new drugs include specific antibodies against growth 
factors or their receptors and small molecules that interfere with signal 
transduction pathways regulating the cell cycle, gene transcription and survival in 
cancer cells. Some of the drugs have a single specific target whereas others may 
have multiple targets. Because the targets of this therapy are processes that 
are dysregulated only in cancer cells. These agents do not share the same side 
effects in normal tissues.  There is a doubt whether sequential chemo radiotherapy 
or concurrent chemo radiotherapy is better. 
                                          The RTOG trial conducted by Forastiere et al in locally 
advanced laryngeal cancer. A total of 547 patients were randomly assigned to three 
groups. The first group received radiotherapy alone. The second group received 
induction chemo [CDDP+5FU]radiotherapy. This group was given concurrent 
chemo radiation using cisplatin. The end point of the study was laryngeal 
preservation. 
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 At two year proportion of patients with intact larynx. 
1. Concurrent chemo radiation arm was 88%.  
2. Induction chemo arm (75% p=0.005).  
3. Radiation alone arm (70% p=0.001). 
The locoregional control.  
1. Concurrent arm (78%).  
2. Induction arm (61%).  
3. Radiation alone arm (56%).  
The overall survival was similar in both groups.  
The high grade toxicities  
1. 82% in concurrent arm. 
2. 81 % in induction arm. 
3. 61% in radiation alone arm.  
This trial established the superiority of concurrent chemo radiation. Although the 
toxicities were higher in the concurrent chemo radiotherapy arm.  
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 There are certain important issues over superiority of concurrent chemo 
radiation.                  
 1. Whether in the radiation alone arm adequate dose of radiation is delivered. 
Improper dosage resulting in decreased effectiveness. 
2. Toxicity associated with concurrent chemo radiation. The completion 
radiation in time should be given utmost importance. Stoppage of radiation 
during treatment can happen if patient experiences increased toxicities. The 
chance of accelerated repopulation is very high in this setting. It can 
adversely affect the outcome of treatment.  So selection of optimal schedule 
for chemo radiation is important. Effective management of toxicities by 
providing adequate supportive care is most important.  
RADIOBIOLOGICAL BASIS OF CONCURRENT CHEMO RADIATION:  
                           The difference between tumour cells and normal tissues is 
critical for determining the therapeutic ratio. Tumour cells have accelerated 
cell proliferation, hypoxia and acidity. These are not present in normal cells.  
Assessment of resistance to radiation and different chemotherapeutic 
agents are also important. Combination of radiation and chemotherapy 
should separate the distance of resistance. Independent toxicity is another 
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strategy that needs to be exploited. Combination of chemotherapeutic 
drugs along with radiation should increase the toxicities of each other. 
 
                           Additive effect: Individual cytotoxicity of the drug + 
individual effect of the radiation overall cell killing. Supra additive effect : 
cell killing in chemo radiotherapy  greater than the cell killing by individual 
cytotoxic agents. This happens when chemotherapeutic agents interact 
with radiation and potentiates the effects of radiation. Chemotherapy 
drugs decrease the number the cancer cells by their independent 
cytotoxicity. Thereby rendering the residual cancer cells more susceptible 
to radiotherapy.  Chemotherapy drugs also acts on microscopic tumour 
cells in circulation and kills them. This killing prevent distal relapses. 
                        Sensitivity to radiation:      1. Cellular hypoxia 
                                                                        2. Cell cycle age distribution  
                       Chronic hypoxia  amplification of certain oncogenes like ras, c- 
myc, c-raf-1. These genes are associated with increased resistance to radiation. 
Also the radiation generates oxygen free radicals which damages DNA. For the 
production of free radicals oxygen is required. The third mechanism of interaction  
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of radiation and hypoxia is oxygen fixation hypothesis. The DNA damages made 
by radiation become permanent in presence of oxygen. This is mainly due to 
oxidation of DNA repair enzymes which are active only in their reduced form. 
Thus by combining radiation with a chemotherapeutic drug which is active against 
hypoxic cells, we can overcome this resistance to radiation.  
                         Most of the chemotherapeutic agents kill proliferating cells in the 
well oxygenated area. Tumours lies close to capillaries are easily accessible to 
chemotherapeutic agents. The bulk of the tumour is decreased and the interstitial 
pressure falls during the killing of well oxygenated cells. This result in opening of 
closed capillaries and previously hypoxic cells become oxygenated. Since the 
tumour shrinks, the previously hypoxic areas move nearer to capillaries. Finally 
the loss of hypoxic cells results in more availability of oxygen to previously 
hypoxic cells. 
 
   
REIRADIATION: 
                               There are lot of emerging theme among many of the 
published series for reirradiation. One among them is long-term survival can 
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be achieved with re-irradiation for recurrent or new primary head-and-neck 
cancer, particularly for those with long disease-free intervals between 
radiation courses and small, isolated lesions. 
                                         Surgical resection has been the mainstay of therapy for 
recurrent head and neck cancers. The low cure rates questions whether the modest 
benefits have advantage over the increased morbidity and toxicities of the 
treatment . Surgery can be technically challenging due to difficulties of operating 
in previously manipulated or irradiated tissue. The proximity to critical structures 
such as the carotid artery, skull base, esophagus, and trachea plays an important 
role in resectable lesions to achieve  
Adequate response. Surgery in the previous treated area has lot of factors which 
predicts the outcome of the disease. 
1. Poor vascularity. 
2. Healing properties of the previously treated area. 
3. Incomplete margins. 
4. Graft uptake. 
5. Facial reconstruction. 
6. Requires base skull surgery in advanced lesions in recurrence 
setting. 
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                        In INDIA most of the institutions lack the facilities for base skull 
surgery. Adequate expertise in the field of surgical oncology is lacking which 
indirectly leads to under development of advanced techniques. 
                             Another alternative mode of treatment for this recurrent patients 
is palliative chemotheraphy. First concern about Palliative chemotherapy is , it is 
not a curative intent. Lot of trails have shown only less survival when compared to 
the other modes of treatment. One major concern is no established trails or 
established chemotheraphy present till now to increase the survival rates. There is 
also lot factors determining the chemotherapy. 
1. Penetration of drugs. 
2. Resistant to drugs. 
3. Toxicities. 
4. Availability of drugs in the tumour area. 
5. Surrounding changes in the tumour area resisting the drug. 
6. Tolerance of the patient. 
                                        
                         Inspite of this factors chemotherapy alone has traditionally been 
considered in this setting. But the response rates have been poor with low survival 
and locoregional control.  Nearly  all patients dying of disease progression within 
months. 
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                                               Reirradiation has its own advantages and 
disadvantages in this recurrent head and neck cancer setting. Because of the risks 
associated with re-irradiation to the head and neck, strafication of patients is 
needed utmost. The identification of patients who benefit from this approach is 
much important. However, the selection criteria for re-irradiation remain poorly 
defined. It vary across institutions among countries and continents. The basic 
patient characteristics include 
1.  Performance status. 
2. Baseline functioning. 
3. Age. 
Studies have suggested that baseline organ function is one of the most critical 
predictors of the outcome after re-irradiation. Re-irradiation dose was the most 
important prognosticator for overall survival 
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FACTORS: 
 
1. INTERVAL BETWEEN RADIATION TREATMENT:            
The single most relevant factor is the interval between initial radiation 
therapy and the previous radiation therapy. The gap between the doses is 
important as it predicts directly the  
A. Outcome of toxicities. 
B. treatment tolerance 
C. resistant to treatment  
D. dose calculation  
Increased interval between RT courses lower the probability of 
developing severe complications. The likelihood of local control also 
decreases. Most trials used interval of 6 months for re-irradiation of 
recurrent head and neck cancers. If irradiated less than 6months toxicities 
will be much higher and resistant to radiation and chemotherapy is higher 
than what we expect. 
2. Several studies have also demonstrated the importance of tumor bulk at the 
time of re-irradiation in predicting the outcome. As the environment 
surrounding the normal tissue is already disrupted the increased tumour 
burden with hypoxia will lead to decreased tumour control. Hypoxic regions 
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will be areas of poor penetration for the drugs and decreases the maximum 
benefit attained from chemotherapy. 
 
3. Another major consideration is the dose received by critical structures. Such 
as the spinal cord, optic structures, mandible, brain, and carotid arteries. 
These organs must be protected during the second treatment course. This 
will help to determine the dose that can be allowed to these structures. A 
detailed plan of the original treatment is also required for evaluation of the 
candidate patients. Consideration of late toxicities for providing better 
quality of life to the patient is utmost importance while practice 2D 
technique using cobalt 60. The organs involved are going to play a vital role 
as if their toxicities limit has crossed their tolerance level it will produce life 
threatening complications. 
 
          A common practice is to assume a previous delivery of 50 Gy to the 
spinal cord and brainstem during the initial RT, unless the dosimetry records 
are available and demonstrated otherwise.  Many institutions have assumed a 
50% dose tolerance recovery of CNS structures if the interval between RT 
courses is 1 year. This assumption might be conservative and might apply to 
all tissues not exhibiting clinical levels of radiation injury from the first 
treatment course. 
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                        Decisions regarding re-irradiation should ideally be made in a 
multidisciplinary setting. Careful review of all imaging studies, and previous 
radiation fields with dosimetry is needed. Biopsy-confirmed evidence of 
pathologic recurrent disease is imperative. Because radiographic and clinical 
suspicion can often be complicated by inflammatory changes. 
 
                      Appropriate imaging should be done to rule out cartilage necrosis or 
arytenoid edema from the previous treatment. These complicate the present 
scenario   with high risk of aspiration and/or airway closure. Re-irradiation will not 
be offered to a patient with known osteoradionecrosis. Severe cervical fibrosis also 
influence the management with reirradiation in recurrent head and neck cancers. 
Doses to the mandible should be considered as it can lead to osteoradionecrosis 
which can complicate the patient his quality of life. Doses can be planned 
assuming 50% recovery from the previous doses for the present planning doses. 
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WHY IT IS NEEDED??? 
                    Most of this population will die as a direct consequence of 
uncontrolled tumor growth at the primary site. If left untreated, the prognosis of 
patients with is poor. The median survival is only a few months. The importance of 
locoregional control in the setting is unquestioned. For patients with recurrent 
disease, considerations for additional therapy must be balanced between the 
prospects of disease control and toxicity. Although the competing risk of 
developing distant 
metastasis is significant, most of this population will die as a direct consequence of 
uncontrolled tumor growth at the primary site. Studies have shown that if left 
untreated, the prognosis of patients with locoregionally recurrent head-and-neck 
cancer is poor, with a median survival of only a few months. 
 
A common practice is to assume a previous delivery of 50 Gy to the spinal cord 
and brainstem during the initial RT, unless the dosimetric records are available and 
demonstrated otherwise. On the basis of preclinical data, many institutions have 
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assumed a 50% dose tolerance recovery of CNS structures if the interval between 
RT courses is 1 year. This assumption might be conservative and might apply to all 
tissues not exhibiting clinical levels of radiation injury from the first treatment 
course. 
 
How much? 
                                     Higher the dose delivered, the greater the probability of 
disease control. Experimental data have suggested that cumulative biologically 
equivalent doses of #130 Gy. That  can be safely tolerated in the recurrent  head 
and neck cancers. Most trials have recommended limiting the cumulative spinal 
cord dose to 50 Gy. The proximity of the tumor to critical structures must also 
be considered. Preclinical data have attempted to determine the normal tissue 
tolerance to reirradiation. Some have suggested that the soft tissue can tolerate 
approximately 90% of total dose . The dose is heavily dependent on the volume of 
overlap and the interval between radiation courses. Some research papers evaluated 
greater 60GY of reirradiation dose can achieve good biological control than the 
doses <60GY.  
 
 
 
 
 35 
 
 
 
 
 
TOXICITIES: 
                   During a course of H&N radiation therapy, there are predictable side 
effects that are experienced by the majority of patients: mucositis, fatigue, loss of 
taste acuity, radiation dermatitis, and xerostomia. Typically patients will begin to 
experience mucositis during the third week of radiotherapy. This initially manifests 
as mucosal blanching within the treatment field, but can progress to patchy or 
confluent mucositis. Initially patients can be treated with an over-the-counter pain 
reliever, but once patients develop grade II or III mucositis, they will commonly 
require narcotic analgesics for adequate pain control. 
                       The combination of dysphagia and mucositis can result in significant 
nutritional compromise necessitating intravenous hydration and parenteral 
nutritional supplementation. Nausea associated with treatment can also further 
complicate the nutritional status. These acute toxicities can become particularly 
pronounced in the setting of intensified radiation fractionation schedules or 
combined chemo radiotherapy. Patients may require prophylactic anti emetics. In 
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patients receiving concurrent radiotherapy and platinum-based chemotherapy, 
there is clear potential for myelosuppression; therefore, blood counts should be 
monitored regularly. Signs or symptoms of infection should be addressed 
promptly. Finally, xerostomia can become problematic during the course of 
radiation.  
                   Ultimately, patients can be reassured that the majority of these side 
effects, with the exception of xerostomia, are temporary and will resolve several 
weeks to months following completion of therapy. As noted, one of the acute side 
effects of radiotherapy that can become permanent is xerostomia. Chemical and 
physical modifiers of the radiation response have been utilized to reduce long-term 
xerostomia.  
                        The free radical scavenger amifostine has the potential to reduce 
radiation effects on normal tissues if administered just prior to each radiation 
fraction. A randomized phase III trial demonstrated a reduction in the severity of 
the acute and chronic grade 2 or higher xerostomia in patients who received 
amifostine during RT. Dose limiting toxicities commonly include hypotension and 
nausea. There has been concern over possible tumor-protective effects of 
amifostine, but a recent metaanalysis does not suggest this. However, data 
supporting the use of amifostine to reduce xerostomia has been generated in the 
setting of conventional radiation, and the magnitude of benefit on xerostomia of 
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parotid-sparing IMRT appears greater than that of amifostine. Therefore, the 
ultimate value of amifostine in patients with advanced H&N cancer, especially in 
the setting of IMRT, has been called into question. 
                          Currently there is no universal standard recommendation across 
treatment centers for the use of this radio protector. In some cases, hypopharynx 
cancer patients who complete a course of radiation therapy will be noted to have 
persistent laryngeal edema on subsequent follow-up visits. Although in the early 
posttreatment phase (in fact up to 24 months), significant or newfound edema 
should raise suspicion regarding the possibility of persistent or recurrent disease; 
the majority of patients who receive high-dose radiation across major segments of 
the larynx and hypopharynx will manifest some degree of edema, mucosal 
congestion, and eventual fibrosis. Generally, this collateral damage is a tolerable 
chronic toxicity with modest impact on patient quality of life. However, in 
approximately 10% to 15% of patients, this edema is severe enough to cause 
significant airway and swallow function compromise requiring tracheostomy. 
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DENTAL CARE: 
                       Prior to the initiation of head and neck radiation, a careful oral and 
dental evaluation, including a panoramic radiograph, should be performed. 
Dentition in poor condition should be identified and considered for extraction to 
minimize the subsequent risk of osteoradionecrosis. Specifically, those teeth that 
will reside within the high-dose radiation volume that demonstrate significant 
periodontal disease, advanced caries, or abscess formation or are otherwise in a 
state of disrepair should be extracted. In addition, impacted teeth, unopposed teeth, 
and teeth that could potentially oppose a segment of a resected jawbone should be 
considered for extraction if they are anticipated to reside within the high-dose 
radiation treatment volume. Extraction of marginal teeth should also be considered 
in patients who are deemed unable to maintain adequate oral hygiene.  
                       Radiation can induce several chronic effects in the oral cavity that 
warrant routine surveillance. Radiation can impair bone healing and diminish the 
capacity for successful recovery following trauma or oral surgery. For this reason, 
elective oral surgical procedures including extractions must be very carefully 
considered after radiation. Escalation of dental caries deriving from xerostomia 
following radiation is well recognized. Radiation of the major salivary glands 
changes the nature of salivary secretions, which can increase the accumulation of 
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plaque and debris, reduce salivary pH, and reduce the buffering ability of saliva. 
This creates an environment in the oral cavity, which predisposes patients to caries. 
During a course of radiation to the oral cavity, simple techniques such as the use of 
custom molds to absorb electron backscatter can diminish hot-spot mucositis from 
dental fillings and improve treatment tolerance. Attention to oral hygiene with 
frequent dental follow-up examinations and cleanings, daily fluoride therapy, 
flossing, and brushing should be an integral component of the education and post 
radiation care of patients who undergo radiation to the oral cavity. 
PROGNOSTIC FACTORS: 
• PRIMARY-site, size, extent& regional / distant Mets 
• NODES-single most imp in survival 
• HISTOLOGY differentiation-less imp 
• PREVIOUS H&N cancer-major 
• Cigarette&tobacco-25 fold risk, abstain-30% reduction in 1-9yrs quit, 50% 
reduction in >9yrs quit 
• HPV related – better prognosis regardless of treatment 
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POST RADIATION DISABILITIES: 
 Degree of functional deficits depends on extent and type of radiation therapy  
 Side effects – common, directly influence communication and swallowing 
functions. 
  Effects of radiation therapy change over time and may involve mucosal 
tissue and muscle function.  
RADIATION THERAPHY SIDE EFFECTS: 
 Severe pain 
 Reduced salivary flow,  
 Edema 
 Restricted movement 
 Nausea and vomiting 
 Reduced appetite 
 Reduced senses of taste and smell 
 Dental problems.  
 
 
 
 
 41 
 
POST CHEMO DISABILITIES: 
 Post Chemo Disabilities – impaired communication and swallowing 
functions.  
 Fatigue 
 Nausea and vomiting 
 Loss of appetite 
 Reduced senses of taste and smell 
 Gastrointestinal irregularities 
 Oral dryness and sores in the mouth.  
TRACHEOSTOMY ISSUES  
 The primary roles of tracheostomy in the treatment of head and neck cancer 
after surgical interventions are to maintain an open airway and provide 
access for pulmonary toilet during the recovery period. 
  On some occasions, a tracheostomy tube can be placed during or after 
radiation treatment to alleviate respiratory distress resulting from edema of 
the airway.  
  Placement of a tracheostomy tube reduces airflow and air pressures within 
the upper aero digestive tract that support speech and swallowing functions. 
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  Reduction or elimination of expiratory airflow reduces cough effectiveness 
and disturbs the normal apneic interval during swallowing. 
 Placement of a tracheostomy tube has been associated with increased risk of 
aspiration resulting from disruption to normal swallow biomechanics.  
 This procedure may tether the larynx, reducing laryngeal excursion during 
swallowing. 
  A more pronounced tethering effect may result from large-diameter or 
inflated-cuff tracheostomy tubes. 
  Reduction in laryngeal excursion contributes to incomplete clearance of 
materials from the pharynx during swallowing.  
 Subsequently, post-swallow residue can be aspirated. 
  Also, use of a high-pressure cuffed tracheostomy tube may increase 
pressure in the upper esophagus or impinge on the esophagus, causing 
backflow and aspiration of contents into the airway. 
  Patients continue to aspirate around the cuff because of incomplete sealing 
or leaks after movement or subsequent to large-volume swallows. 
  For these reasons, clinicians should exercise caution when initiating oral 
feeding in patients with a tracheostomy tube with an inflated cuff.  
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RADIATION THERAPY IMPACT ON SPEECH, VOICE, AND 
SWALLOWING FUNCTIONS: 
 Radiation therapy contributes to a variety of mucosal and muscle tissue 
changes, which can complicate existing speech, voice, or swallowing 
difficulties and create new problems.  
 Frequent side effects of radiation therapy that may have a negative impact 
on speech, voice, or swallowing functions include mucositis, xerostomia, 
and edema.  
  As a result of these complications, patients may experience pain, dryness, 
and limited mobility of structures required for successful speech, voice, or 
swallowing functions.  
 Difficulties that persist after completion of radiation therapy may be linked 
to fibrosis or atrophy in muscles or peripheral nerve deficits, or both. 
 In addition, thickened secretions in the oropharynx, hypopharynx, or larynx 
alter speech and voice clarity and contribute to reduced swallow efficiency.  
 Consequently, reduced swallowing efficiency results in prolonged meal 
times, post-swallow residue requiring multiple swallows to clear, and 
difficulty controlling the direction of a swallowed bolus, leading to potential 
risks of tracheal aspiration. 
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OROPHARYNGEAL SWALLOWING PROBLEMS ASSOCIATED WITH  
RADIATION THERAPY FOR HEAD/NECK CANCER : 
Bolus control deficits (63%). 
Small amounts per bolus. 
Multiple swallow attempts per bolus. 
Increased mealtimes. 
Reduced frequency of swallowing. 
Dry mouth (92%). 
Pain (58%). 
Altered taste (75%). 
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TOLERANCE LEVELS OF OAR: 
Optic nerve and Chiasma 54 GY 
Brain stem 54 GY 
Spinal cord 45 GY 
Temporal lobes 60 GY 
Inner ear 50 GY 
Pituitary 45 GY 
Eyes 35 GY 
Parotids <26 GY in at least 1 gland 
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TRAIL:  
1. Recently published Phase III multi institutional trial of 130 patients from 
Europe. Re-irradiation could also have a role in the postoperative setting. 
The use of postoperative re-irradiation with concurrent 5-fluorouracil and 
hydroxyurea increased both acute and late toxicity compared with 
observation alone, a significant improvement in disease-free survival was 
nevertheless reported with the more aggressive regimen. Given the 
impressive results of that trial, it might be reasonable to offer re-irradiation 
to select postoperative patients with high-risk surgical feature such as 
positive margins or extracapsular nodal spread, depending on other patient 
characteristics, as previously discussed. 
 
2. The Radiation Therapy Oncology Group trial 96-10 [prospective] of 86 
patients. IT includes patients who had undergone primary RT 3 years. 1-year 
overall survival rate of 48% in  >3yrs arm. 1-year overall survival rate of  
35% for patients treated within 3 years. The acute and late toxicities 
however was not insignificant. In the RTOG 96-10 trial, RT was delivered 
using standard 2D technique. Lateral -opposed, single wedge paired, oblique 
fields targeting the gross tumor. The margins were generous and it is not 
similar to that of primary radiation treatment planning CTV. Three-
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dimensional planning using computed tomography (CT) was recommended. 
Similarly, in the series by De Crevoisier et al.  all patients were treated by 
two-dimensional techniques using cobalt-60 beams. RTOG 96-10 treated 
with 60 Gy at 1.5-Gy, twice-daily fractions. Chemotherapy administered 
every other week with 5-fluorouracil and hydroxyurea. Although nearly all 
patients successfully completed reirradiation. Only 6 treatment-related 
fatalities were reported. 
 
3. Salama et al.  
    
          DOSES 
              3YEAR 
OVERALL    
SURVIVAL 
 
LOCOREGIONAL 
CONTROL 
        <58GY                 6%           33% 
         >58GY                30%           56% 
 
This study estimated the total reirradiation dose for better outcome. This 
study states that >58GY needed for achieving the locoregional control. 
 
 
4. Watkins et al. also showed that re-irradiation doses >58 Gy improved 
survival. 
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5. Most of the experimental data have suggested biological equivalent doses.  
A.Cumulative biologically equivalent doses of #130 Gy. 
           B.Cumulative spinal cord dose to 50 Gy. 
 
6. De Crevoisier et al. compared three re-irradiation schedules.  
a. conventional fractionation to 65 Gy using 2-Gy fractions (without 
chemotherapy);  
b. split-course conventional fractionation to 60 Gy. Using 2-Gy fractions 
delivered on alternating weeks (with concurrent chemotherapy);  
c. split-course hyperfractionated re-irradiation to 60 Gy. Using 1.5-Gy 
fractions delivered twice daily (with concurrent chemotherapy).  
Given the wide range of patients treated and limited numbers, it was not 
surprising that no significant differences were observed among these 3 
schedules with respect to any of the endpoints analyzed. 
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AIMS AND OBJECTIVES 
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AIM OF THE STUDY: 
 
 
Primary Objective: 
To assess the immediate locoregional response rates of unresectable locoregionally 
recurrent squamous cell carcinomas of the head and neck treated with reirradiation 
and oral capecitabine. 
 
Secondary Objective(s): 
To assess the acute toxicities of the treatment. 
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          MATERIALS AND METHODS 
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MATERIALS AND METHODS 
 
This study is a prospective single arm study involving previously treated 
patients with locally recurrent unresectable squamous cell carcinomas of head and 
neck. Thirty patients with histologically proved squamous cell carcinomas 
registered in our department were included. The accrual of the patients was started 
after obtaining consent from the ethical committee for conducting this study in our 
institute. The informed consent was obtained from all the patients included in the 
study. The study period was from march 2015 to september 2015. 
 
Subject Selection:  
Biopsy proven squamous cell carcinoma of head and neck with performance status 
ECOG 0-2 
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INCLUSION CRITERIA:  
• Biopsy proven recurrent squamous cell carcinoma of the head and neck 
• Primary tumour sites: oral cavity, oropharynx, hypopharynx, larynx 
• Without any evidence of distant metastases 
• Age 18-60 years 
• ECOG performance Status ≤2 
• Ineligible for definitive surgical resection 
• Anticipated cumulative spinal cord dose will be limited to 50GY 
• Maximum prior RT 75GY 
• Recurrence appeared atleast 6 months after the end of prior definitive 
radiotherapy 
• Submission of prior radiotherapy records 
• Adequate bone marrow, hepatic and renal functions 
• No associated comorbidities  
• Signed informed consent prior to initiation of protocol specific procedure 
 
 
EXCLUSION CRITERIA: 
 Non squamous histology 
 Tumours of the nasal cavity, paranasal sinuses, nasopharynx, salivary glands 
 Previously received treatment for any other malignancy 
 Inadequate hepatic and renal functions and bone marrow reserve 
 Patients not consenting for chemotherapy at any point in the treatment  
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PRE-TREATMENT WORK UP AND GENERAL MEASURES: 
1. Biopsy from tumour 
2. Complete blood count, renal and liver function tests weekly 
3. CT scan Neck (From Base of Skull to Root of Neck) – Plain and Contrast before 
start  
   Of treatment and after completion. 
4. Chest X ray – PA view, blood grouping & typing 
5. Dental evaluation 
 
STUDY DESIGN:     SINGLE ARM PROSPECTIVE STUDY 
 
 
PATIENT PREPARATION 
All patients were advised to quit smoking and alcohol. Studies have shown that 
smoking and alcohol intake during radiotherapy has shown poor results. Shaving 
must be done before radiation treatment for uniform distribution of dose. 
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DENTAL PROPHYLAXIS  
 
      Dental prophylaxis has been done in all required patients. It is done  in 
the form of dental filling, scaling and extraction. Prophylactic antibiotics were 
started 2-3 days prior to the extraction. Then they are maintained on antibiotic 
coverage for 7 to 10 days. Complete hygiene instruction were given.  
Precautionary instruction about the premature use of prosthesis and trauma were 
given. 
       Patients were instructed to clean their teeth after each main meals. They 
are advised to  use soft brush. They were also instructed to use soda bicarbonate 
mouth wash. The patients were instructed to prepare mouth wash themselves. They 
were advised to dissolve one pinch of soda bicarbonate powder to glass of water. 
 
NUTRITIONAL CARE 
                         Patients receiving radiation therapy to head and neck have specific 
feeding problems. All the patients involved in the study were encouraged to take 
adequate nutrition. This important care will prevent excessive weight loss. 
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Ingesting food by mouth is the preferred method of feeding. However nasogastric 
tube is inserted if required. In extreme cases of concurrent chemo radiation, intra 
venous hyper alimentation is given. 
 Specific meal plans were devised for individual patients. The meal plans 
were maintained as close to the normal diet. Calories equal to normal person diet 
maintained even when the texture and consistency were changed. The patient’s 
weight was checked on a weekly basis. Weekl evaluation how well the patient is 
eating. Depending on the weight the meal plans are revised on a weekly basis. The 
meal plans are advised with increased caloric and protein requirements of the 
patient. This is important for the regeneration the tissues. 
 From the third week patients were advised to take mainly liquid diet.  
Radiation induced reactions will start by 3
rd
 week.  The patients with radiation 
induced dysphagia and mucositis are required specific plan. The specific meal plan 
was changed to incorporate mainly liquid diet. During the fourth week of radiation 
xerostomia will be the main cause of dysphagia. The patients will be having 
difficulty in swallowing solid foods. The dryness of mucosa will cause the solid 
foods to stick to mucosa and induces vomiting.  They are advised to take fresh 
juices like apple and guava and avoid citrus fruits like lemon and Mozambique. 
Home- made high protein formula using banana, egg, milk and sugar were advised 
twice daily.  
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RADIATION THERAPY: 
Patient Set Up: 
All patients were treated using Theratron phoenix cobalt unit. Patients were 
treated in right and left lateral positions.  
Target Volume: 
Target volume included tumour along with 2 cm clearance.   
Portals 
 Two opposing lateral portals were used. 
Dose 
           Radiotherapy will be delivered by opposing lateral fields with a telecobalt 
machine in 200cGy per fraction for 5 days a week. Reirradiation up to a 
cumulative dose of 120Gy including previous RT dose will be given. Oral 
T.Capecitabine 900mg/m2 in divided doses given on treatment days. Entire 
treatment is to be completed in less than 7 week time.  
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CHEMOTHERAPY PROTOCOL 
T.CAPECITABINE 
Dose      900mg / m
2
 daily 
Schedule     BD dose on all RT days 
   
PRE TREATMENT ASSESSMENT 
 Regarding radiation the following toxicities were assessed during every 
week of radiation. 
1. Skin reactions 
2. Mucositis 
3. Xerostomia 
4. Dysphagia  
5. Laryngitis 
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INTRA TREATMENT ASSESSMENT  
1. Prior RT dose  
2. Prior RT field and extension 
3. Prior staging and extension of tumour 
4. Prior toxicity assesement 
5. Prior chemotherapy   
Regarding radiation the following toxicities were assessed during every week of 
radiation. 
1. Skin reactions 
2. Mucositis 
3. Xerostomia 
4. Dysphagia  
5. Laryngitis 
Regarding capecitabine the following toxicities will be assessed during 
every week. 
1. Nausea 
2. Vomiting 
3. Abdominal pain 
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The toxicities were assessed using RTOG Acute Morbidity Scoring Criteria and 
Common Toxicity Scoring Criteria. The toxicities were assessed every Monday 
and recorded. All the toxicities are managed according to the guidelines. 
For prevention of mucositis all patients were advised to maintain good oral 
hygiene. Soda bicarbonate mouth wash gargle 5 -6 times a day is advised. Patients 
were also instructed to apply honey.  
a. 15 minutes prior to the radiation. 
b. 15 minutes after radiation. 
c. 12 hours after radiation.  
When patients developed mucositis, they were treated using NSAIDS, 
steroids and antibiotics. NSAIDS used was Diclofenac tablets 50 mg twice 
daily. The steroid used was dexamethasone 4 mg IV twice daily when the 
patients developed grade III toxicities. All patients with grade III mucositis 
were under broad spectrum antibiotic coverage. In case of grade II 
pharyngitis and laryngitis patients were treated using NSAIDS and 
antitussives. In case of all grade III toxicities, steroids were incorporated into 
management. 
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Hemoglobin was checked every week. If hemoglobin level goes below 10 g/dl 
%, the patients were given packed cell transfusion. If the count goes down below 
normal value. (Absolute neutrophil count below 2000). The patients were given 
Inj. G-CSF 300 mg sub cutaneous once daily for three days.  
 
 
RESPONSE ASSESSMENT 
Response to the therapy was assessed six weeks after completion of 
treatment. Both clinical and radiological assessment was done. Response 
assessment was done using RECIST criteria version 2.0. Assessment of complete 
response, partial response, no response or progressive disease was done. 
All patients with complete response after the protocol were observed on 
monthly follow up. The patients with residual disease or progressive disease were 
assessed for salvage surgery.  
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RESULTS 
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AGE DISTRIBUTION: 
                      The age distribution in our study falls maximum in the age group 40-
50 and 50-60. The chronicity of the exposure to tobacco related products and other 
forms of tobacco are the main causes for this age distribution. The young adults are 
the group which now in the increasing side of occurrence of head and neck cancers 
in India.  
 
 
                                                                                                           
AGE GROUP 
 
                                                                   
NO. OF PATIENTS 
       30-40            6 
       40-50            12 
       50-60            11 
       60-70            1 
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SEX DISTRIBUTION 
              SEX           NO. OF PATIENTS 
              MALE                     25 
              FEMALE                      5     
 
               Males are the dominant group due to the established cause of tobacco 
usage in the males comparing to women. In females also pan chewing in the form 
of areca nuts with leaves are a cause for head and neck cancers. 
ECOG PERFORMANCE STATUS 
          ECOG           NO. OF PATIENTS 
         1                        12 
         2                        18 
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                         ECOG performance status is one of important tool in determining 
the management decision for reirradiation. The tolerance of the patient towards 
radiation and chemotherapy tolerance are decided by the performance status along 
with age and other factors.  
SITE: 
                 SITE                NO OF PATIENTS 
            ORAL CAVITY                       12 
            OROPHARYNX                        8 
             HYPOPHARYNX                        7 
              LARYNX                         3 
 
                                The common site of recurrence in our study is oral cavity. 
Oropharynx hypopharynx larynx falls after oral cavity. Among the oral cavity 
cancers tongue is the common site of recurrence. 
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STAGING 
       r TUMOUR           NO.OF PATIENTS 
       rT0                        00 
       rT1                        00 
        rT2                        12 
         rT3                        16 
        rT4                        02 
 
                      Stage at which patient presents is an important prognostic indicator 
for treatment outcome. In our study most of the patients present with T3 and T2 
tumour stage. The patients who are all not eligible for surgery are managed with 
reirradiation. T1 lesions are amenable for surgery with clearance comparing to the 
t3 and t4 lesions. In most of the single institution trails staging is considered as 
important prognostic factor. De gustave et al.  large single institution trail 
concluded staging is one of the important predictor for outcome of  reirradiation in 
head and neck cancers. 
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NODAL STAGING 
 
 
                      NODAL                   NO.OF PATIENTS 
                          N0                               15 
                          N1                               09 
                          N2                               06 
 
                       Local recurrence is the most common of failure than comparing the 
regional recurrence in recurrent head and neck cancers. Regional recurrence with 
local recurrence is less common presentation comparing to patients presenting 
either with local recurrence alone or regional recurrence alone. 
 
PREVIOUS TREATMENT: 
 
       PREVIOUS TREATMENT              NO.OF PATIENTS 
RADIATION ALONE                         05  
RADIATION  SURGERY                        03 
SURGERY  RADIATION                        04 
 RADIATION + 
CHEMOTHERAPY 
                       18 
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In our study most of the patients had radiation + chemotherapy as the previous 
treatment. The radiobiology of the tumour is important such that vascularity 
perfusion tumour resistance are compared to surgical area will be altered. It also 
suggest that most of the advanced nature of the diseases recurred. 
 
PREVIOUS CHEMOTHERAPY 
 
  CHEMOTHERAPY RECEIVED                NO. OF PATIENTS 
      WEEKLY CDDP                 07 
      3 WEEKLY CDDP                 11 
      CDDP + 5FU                 08 
      CDDP+ PACLITAXEL                 05 
 
                  
                                There are no solid evidence suggesting the radiobiology of 
chemotheraphy in recurrent setting. Common factors needed for the chemotherapy 
in the setting of reirradiation of head and neck cancer is perfusion of the drug, 
availability in the tumour area, decreased drug resistance, radiosensitive effect, 
cumulative effect of cell killing [tumouricidal dose] less side effects. Full dose 
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chemotherapy using cisplatin 5-fu paclitaxel combinations will produce toxicities 
to the normal tissues in additive with radiation. 
RADIATION FRACTIONATION 
  PREVIOUS   
FRACTIONATION 
       NO OF PATIENTS 
            CONVENTIONAL               19 
      HYPERFRACTIONATION              08 
           ACCELERATED              03 
 
                  Different fractionation schedules in the previous treatment is also an important 
factor as it can correlate with the late term toxicities. Comparing to conventional 
fractionation, hyper fractionation is having low bed dose in the normal tissue areas. The 
late  toxicity is low when compared to conventional and other fractionations.  
 
PRIOR RT DOSE 
PRIOR RT DOSE    NO. OF PATIENTS 
         70-80 GY               05 
              60-70 GY               21 
              50-60 GY               04 
              40-50 GY               01 
 
The bed dose for the present reirradiation was calculated by using decay factor and 
formula. 
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PRESENT BED DOSE= DECAY FACTOR X TOTAL DOSE [PREVIOUS] 
 
DECAY FACTOR = (T/T+R)0.11 
 
 
 
GAP BETWEEN RADIATIONS 
 
      TIME INTERVAL       NO OF PATIENTS 
      6MONTHS – 1YEAR                02 
        1YEAR- 2 YEAR                06 
        2YEAR -3YEAR                10 
        >3YEAR                12 
 
                    The interval between the radiation is one of the important factor 
determining the tolerance of the treatment and their toxicities. Patients whose 
treatment interval time greater than three years will tolerate better with another full 
dose of radiation dose comparing to the other patients interval doses.  Reirradiation 
even after 6months are practiced in some institutions. Most of the trials reirradiate 
cases after 6months mostly with conformal RT and also with conventional 
technique. 
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FEEDING TUBE: 
 
FT REQUIREMENTS        NO.OF PATIENTS 
    BEFORE RT                  08 
    DURING RT                  10 
    AFTER RT                  12 
 
         Feeding tube requirements indirectly measures the dysphagia. The patients 
who needs of the feeding tube after reirradiation were found to be surviving with 
grade 2 and 3 dysphagia. The patient who requires feeding tube before radiation 
can be due to late toxicity of previously treated radiation or 
odynophagia/dysphagia due to tumour extension in the recurrent setting. 
TOXICITIES: 
                         
 
 
                         We categorized the toxicity of the patient into 
hematologic and non hematologic. In our study comparing to non hematologic 
toxicity hematologic toxicity occurred very less percentage. The chemotheraphy 
used is only produced the GI symptoms like nausea vomiting diarrhea abdominal 
pain. Radiation treatment is associated mostly with non hematologic toxicities like 
soft tissue toxicity, mucous membrane and skin. 
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HEMATOLOGIC: 
 
 GRADE1 GRADE2 GRADE3 GRADE4 
NEUTROPENIA 35% 14% 02% 0% 
THROMBOCYTOPENIA 25% 0% 0% 0% 
LEUCOPENIA 48% 0% 0% 0% 
  
NONHEMATOLOGIC 
 
 GRADE1 GRADE2 GRADE3 GRADE4 
SKIN 63% 25% 02% 00% 
MUCOSA 70% 21% 01% 00% 
SALIVARY 
GLAND 
40% 50% 10% 00% 
PHARYNX 45% 43% 12% 00% 
LARYNX 60% 35% 05% 00% 
DIARRHOEA 40% - - - 
 
                     In our study non hematologic toxicities comprises the most. 
The pharyngeal toxicities are the important one influencing the completion of 
treatment. The quality of the patient was reduced in some of the patients due to the 
dysphagia. Most of the patients cope with dysphagia with proper counselling and 
techniques of food intake like change in consistency frequencies matching with the 
requirement of normal person energy and calories. 
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MUCOSITIS:  
 
MUCOSITIS 
GRADE 
NO.OF PATIENTS  MEDIAN 
LIFETIME DOSE 
GRADE 0         00 120GY 
GRADE 1         15 120GY 
GRADE 2         13 110-120GY 
GRADE 3         02 110GY 
GRADE 4         00         - 
 
       The patients who received the mean life time dose of 120 GY had grade 2 
mucositis. The grade 3 mucositis occurred in two patients only with 120 GY. 
The mean life time dose of 120GY is acceptable and tolerance of the patients is 
good with less toxicity. 
        
DYSPHAGIA: 
 
DYSPHAGIA  NO OF PATIENTS MEDIAN LIFE TIME 
DOSE 
GRADE 0             -              - 
GRADE 1            15         120 GY 
GRADE 2            13         120 GY 
GRADE 3            02         120 GY 
GRADE 4             -              - 
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                      Dysphagia increased in both number of patients and in grades. 
Patients with grade 2 toxicity occurs with a median life time dose of 120GY. 
Hence our study represents less toxicity when compared to other single institution 
study were toxicities remains in the higher side. 
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ASSESEMENT OF TOXICITIES: 
 
MUCOUS MEMBRANE: 
 
                  Toxicity assessment was done every week and the results of the 
3weekly assessment is shown below: 
 
 
             In our study mucositis present in all the patients but less in severity. The 
grade 2 mucositis occurred in most of the patients during the 3
rd
 and 6
th
 week. 
Grade 3 mucositis occurred mostly in the 6
th
 week. There is no occurrence of grade 
4 and grade 5 toxicities. Also there is no treatment gap and all patients completed 
the treatment without interruption. But the patients who was irradiated within 6 
months to 1year experienced the grade 3 toxicities. All other patients who 
underwent reirradiation greater than 2years had less mucositis of grade 2. 
 
PHARYNX: 
                                      In our study dysphagia due to involvement of constrictor 
muscles of pharynx is an important toxicity as it interrupts the nutrition for the 
patient. The need of feeding tube is mainly due to pharyngeal toxicities. The 
toxicities are more commonly present in the 3
rd
 and 6
th
 week.  
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SKIN: 
                                 Skin involvement in our study mostly 
comprises grade 1 and grade 2 during the 3
rd
 and 6
th
 week. The patients were not 
suffered any skin infection in the grade 3. All the patients were able to tolerate the 
reirradiation with acceptable toxicity. There is no treatment gap during to the grade 
2 toxicity.  
 
SALIVARY GLAND:                    
 
                    XEROSTOMIA was present in most of the patients before 
starting radiation. This is due to previous exposure of the patient to radiation in 2D 
technique were sparing of the parotid function less. The impact of dryness of the 
mouth producing difficulty in swallowing in our patients is less on the completion 
of the treatment. Because all the patients were accustomed to the xerostomia 
complications. They were advised good oral hygiene and mouth care. Overall in 
our study the complications rate were less and patients were reirradiated with 
acceptable toxicity.  
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LARYNX: 
                 Laryngeal complications including voice change, laryngeal 
edema, thyroid cartilage damage were reported less frequently in our study. Most 
of the patients had voice change during the 3
rd
 and 6
th
 week. The regain voice 
occurred in more than 75% of the patients. The life threating complications 
occurred less commonly. We have not encountered any grade 4 or grade 5 
complications. 
RESPONSE: 
        RESPONSE      NO. OF PATIENTS (%) 
      COMPLETE RESPONSE               16 (53%) 
           PARTIAL RESPONSE                11 (37%) 
            STABLE DISEASE               03 (10%) 
            NO RESPONSE               00 (00%) 
    OVERALL RESPONSE RATE               90% 
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                  we assessed the response with RECIST criteria using imaging 
modality, clinical assessment and with expert opinion from ENT surgeons. In our 
study complete response was increasingly high when compared to the other 
comparable single institution trials. We come to know that our study using the 
reirradiation is superior with good response rate. The patients with partial response 
had symptom relief with the reirradiation. Most of the patients responded to our 
treatment except with some 3 patients with stable disease.  
COMPARING THE DOSES: 
 
 
     RESPONSE          <60GY             60GY 
 NO. OF PATIENTS  NO. OF PATIENTS 
COMPLETERESPONSE           2(12%)           14(88%) 
PARTIAL RESPONSE           3(27%)             8(73%) 
STABLE DISEASE           3(100%)                 - 
NO RESPONSE           -             - 
OVERALL RESPONSE             27%            73% 
 
 
                                     In our study we also compared the doses in which patients 
undergone treatment. The patients received 60GY and above had good response 
when compared to patients received <60GY.  
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DISCUSSION: 
                         We have focused our study on clinical outcome and toxicity. We 
conclude in our study that reirradiation was feasible in recurrent unresectable head 
and neck cancers. The acute toxicity was acceptable even if the patient is 
reirradiated in any intervals of time. In our experience there is a marked increase in 
then response rate comparing to other metaanalysis and single institution trails. We 
also come to know that chemotheraphy alone will not produce superior results 
when comparing to reirradiation. In a study done in Gustave-roussy institute 
included 169 patients with unresectable head and neck cancers 37% had complete 
response and 21% overall response rate at 2yrs. The median survival was 
10months. The rate of mucosal necrosis and osteoradionecrosis is 5-20% and 1-
10% respectively. This study also concluded the incidence and severity of 
toxicities higher when comparable to primary radiation. Comparing to this study 
we had superior results with 53% complete response and 37% partial response. The 
toxicity also occurred less in compared to this study. The acute mucositis grade 3 
and grade 4 were higher in the literature 30% and 40% respectively which is more 
than half percent less in our study. Xerostomia was present in most of the patients 
before starting radiation. This is due to previous exposure of the patient to 
radiation in 2D technique were sparing of the parotid function less. The impact of 
 81 
dryness of the mouth producing difficulty in swallowing in our patients is less on 
the completion of the treatment Hematological toxicities also low in our study. In 
other literature studies the grade 3 and grade 4 neutropenia are higher with other 
chemotheraphy regimens like CDDP plus Hydroxyurea, CDDP plus Paclitaxel, 
CDDP plus 5FU. In our study T.Capecitabine is well tolerated with less side 
effects. The drug concentrating effect and sensitizing effect also comparable with 
that of other regimens. Importantly the grade 5 toxicities are reported in most of 
the institution trails. Our study does not have any grade 5 toxicities. The rate grade 
5 mucositis osteoradionecrosis and carotid blow out occurs in some of the patients 
in other institution trails. In our study there is no adverse events like carotid blow 
out, osteoradionecrosis, fibrosis of constrictor muscles and cervical fibrosis. 
                                         A multi institutional trail of RTOG 9610 published in 
2007. This trial used 5FU and hydroxyurea weekly regimen with 60GY of RT. The 
acute toxicity reported in 17.6% grade 4 and 7.6% in grade 5. This trail used 2cm 
margins for the gross tumour volume. The techniques used are both 2D and 
conformal technique. The interval between the radiation is one of the important 
factor determining the tolerance of the treatment and their toxicities. Patients 
whose treatment interval time greater than three years will tolerate better with 
another full dose of radiation dose comparing to the other patients interval doses. 
The patient who undergone reirradiation >1year had good response and less 
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toxicity compared to the patients undergone reirradiation <1year.  The results are 
comparable with the study and our study even has less toxicity than RTOG study. 
In most of the studies investigators recommended tight margins for the radiation 
field. In the study conducted by Gustave roussy they followed a protocol of 
providing 2cms margins around the tumour. But there is a confusion regarding the 
margins and the toxicities associated. If the spinal cord, brainstem, optic nerve, 
eyes involved in the planned field then it is important to consider tight margins 
instead of providing margins. If we compare other literature studies there is 
divergence in the tumour histology selected, treatment modalities offered, tumour 
localization, patient selected and techniques used.  
                                           Most of the investigators tried to identify the various 
prognostic markers associated with the reirradiation. The tumour size, interval time 
period between primary and secondary irradiation, total dose of secondary 
radiation dose. In some institutions they analyzed the tumour volume and field size 
as prognostic indicator. The total dose >60GY in our institution trail samples have 
better outcome and tolerability than comparing the other research trails. We found 
some prognostic correlation among the tumour volume and tumour field size. This 
is due to the toxicities associated with the field size and the involvement of normal 
tissues in the field.  
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                                        Importantly the higher the dose of radiation is required for 
getting increased response. The chemotheraphy which potentiates the sensitizing 
effect and individual cumulative tumouricidal dose with less side effects is 
important for the better response. Cumulative dose applied to the spinal cord is 
important determinant for field planning and in regards to toxicity. Recent 
radiobiological data suggest some regenerative capacity of spinal cord. The spinal 
cord have some memory regarding the dose of the radiation received previously. It 
has been suggested that the memory decreases as the time increases. It is estimated 
that the radiation-induced myelopathy rate at 60 Gy is about 5% [42] and these 
findings were taken into account for the specification of maximum dose limits in 
our study 
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Conclusion 
  
                          Loco-regional failure of HNSCC in previously irradiated areas are 
bit a complicated. After a full course of (chemo) radiation it pose a challenging 
problem. For radiation oncologists, it remain potentially curable diseases in 
selected cases provided with favourable tumour biology. Whenever feasible, 
salvage surgery remains the standard of care. The feasibility remains 
approximately 20% of the cases. In case of adverse prognostic factors, immediate 
postoperative (chemo-) re-irradiation after salvage surgery can be administered 
safely and significantly improves loco-regional control. Despite relatively high 
rates of late radiation-induced complications, adjuvant (chemo-) re-irradiation 
should be considered in case there is an increased risk on locoregional recurrence, 
such as in case of positive surgical margins and/or lymph node metastases with 
Extra nodal spread. In case of unresectable locoregional failures curatively 
intended (chemo-) radiation should be considered in well-selected cases. We 
conclude that the use of full dose radiation along with T.Capecitabine is feasible in 
recurrent unresectable head and neck cancers. The incidence and severity of 
toxicities are acceptable in our study when compared to other studies. But 
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generally the toxicities due to reirradiation is high compared to the toxicity of 
primary radiation. The life threatening complications are rare. In this approach we 
can expect some long term survivors with complete response. At last when 
compared to chemotherapy alone the disease free survival, overall survival, 
response rates are better with reirradiation. 
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